Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Silvia Di Carlo, Claudia Spinella, Guido Gembillo & Domenico Santoro. (2023) Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert Opinion on Pharmacotherapy 24:15, pages 1737-1746.
Read now
Read now
Valeria Cernaro, Sebastiano Calimeri, Alfredo Laudani & Domenico Santoro. (2020) Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. Therapeutics and Clinical Risk Management 16, pages 871-880.
Read now
Read now
Stuart M. Sprague & Jürgen Floege. (2018) Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opinion on Pharmacotherapy 19:10, pages 1137-1148.
Read now
Read now
Valeria Cernaro, Domenico Santoro, Antonio Lacquaniti, Giuseppe Costantino, Luca Visconti, Antoine Buemi & Michele Buemi. (2016) Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. International Journal of Nephrology and Renovascular Disease 9, pages 11-19.
Read now
Read now
Jinshyun Ruth Wu-Wong & Masahide Mizobuchi. (2014) Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?. Expert Opinion on Investigational Drugs 23:11, pages 1465-1475.
Read now
Read now
Francesco Locatelli, Lucia Del Vecchio, Leano Violo & Giuseppe Pontoriero. (2014) Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opinion on Drug Safety 13:5, pages 551-561.
Read now
Read now
Michael Pennick, Lynne Poole, Kerry Dennis & Michael Smyth. (2012) Lanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding. Renal Failure 34:3, pages 263-270.
Read now
Read now
Mario Cozzolino & Diego Brancaccio. (2007) Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease. Expert Opinion on Emerging Drugs 12:3, pages 341-343.
Read now
Read now
Articles from other publishers (19)
Kamran Mahfooz, Haris Sohail, Ani Gvajaia, Uroosa Arif, Daisy Grewal, Monica Reddy Muppidi, Vanya Vohra, Aamir Tarique & Advait Vasavada. (2023) Rasburicase in treating tumor lysis syndrome: An umbrella review. Cancer Pathogenesis and Therapy 1:4, pages 262-271.
Crossref
Crossref
Valeria Cernaro, Michela Calderone, Guido Gembillo, Vincenzo Calabrese, Chiara Casuscelli, Claudia Lo Re, Elisa Longhitano & Domenico Santoro. (2023) Phosphate Control in Peritoneal Dialysis Patients: Issues, Solutions, and Open Questions. Nutrients 15:14, pages 3161.
Crossref
Crossref
Celina de Jesus Guimarães, Sarah Sant’ Anna Maranhão, Pedro Mikael da Silva Costa & Claudia Pessoa. 2021. Chemotherapy and Pharmacology for Leukemia in Pregnancy. Chemotherapy and Pharmacology for Leukemia in Pregnancy
145
179
.
Dan Martinusen, Judith G. Marin, Elaine Cheng & Wynnie Lau. 2020. Renal Medicine and Clinical Pharmacy. Renal Medicine and Clinical Pharmacy
45
115
.
Himaja Koneru, Anil Pattisapu & Paul D. Bozyk. 2020. Evidence-Based Critical Care. Evidence-Based Critical Care
611
614
.
Yi-Chou Hou, Chien-Lin Lu & Kuo-Cheng Lu. (2018) Mineral bone disorders in chronic kidney disease. Nephrology 23, pages 88-94.
Crossref
Crossref
Yohannes Belay, Ketsela Yirdaw & Bamlaku Enawgaw. (2017) Tumor Lysis Syndrome in Patients with Hematological Malignancies. Journal of Oncology 2017, pages 1-9.
Crossref
Crossref
Yi-Chou Hou, Wen-Chih Liu, Cai-Mei Zheng, Jing-Quan Zheng, Tzung-Hai Yen & Kuo-Cheng Lu. (2017) Role of Vitamin D in Uremic Vascular Calcification. BioMed Research International 2017, pages 1-13.
Crossref
Crossref
Himaja Koneru & Paul D. Bozyk. 2017. Evidence-Based Critical Care. Evidence-Based Critical Care
641
645
.
Leesha L. Barnese. (2016) Risk and prevention strategies can help avert tumor lysis syndrome. Pharmacy Today 22:7, pages 52-54.
Crossref
Crossref
Yoram Yagil, Stephen Z. Fadem, Kotagal S. Kant, Udayan Bhatt, Mohammed Sika, Julia B. Lewis & Dana Negoi. (2015) Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease 6:5, pages 252-263.
Crossref
Crossref
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath. (2015) Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials. Clinical Investigation 5:6, pages 551-559.
Crossref
Crossref
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov. (2015) Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease. Clinical Investigation 5:1, pages 9-21.
Crossref
Crossref
Scott C. Howard, Ching-Hon Pui & Raul C. Ribeiro. 2014. Renal Disease in Cancer Patients. Renal Disease in Cancer Patients
39
64
.
Emilio González-Parra, Carolina Gracia-Iguacel, Jesús Egido & Alberto Ortiz. 2013. Clinical Nutrition. Clinical Nutrition
141
153
.
Emilio González-Parra, Carolina Gracia-Iguacel, Jesús Egido & Alberto Ortiz. (2012) Phosphorus and Nutrition in Chronic Kidney Disease. International Journal of Nephrology 2012, pages 1-5.
Crossref
Crossref
Stephen P. DiBartola & Michael D. Willard. 2012. Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice
195
211
.
Scott C. HowardDeborah P. JonesChing-Hon Pui. (2011) The Tumor Lysis Syndrome. New England Journal of Medicine 364:19, pages 1844-1854.
Crossref
Crossref
A Connor. (2009) Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder. Postgraduate Medical Journal 85:1003, pages 274-279.
Crossref
Crossref